NEW YORK, Aug. 8 – Lexicon Genetics said on Wednesday that Bristol-Myers Squibb has chosen certain drug targets from its LexVision library of mouse gene-knockout data to move into drug development. 

The drug giant's decision is significant, Lexicon Chief Financial Officer Julia Gregory told GenomeWeb , because it is the first time a subscriber to the database has identified particularly promising drug targets. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.